Streetbeat News

Stock Prices

NVST

Envista Holdings (NYSE:NVST) reported Q2 2024 earnings of $0.11 per share, missing the analyst estimate of $0.27 by 59.26%. Sales were $633.1M, below the $646.921M estimate. This represents a 74.42% decrease in EPS and a 4.42% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:11 pm

UPWK

Upwork shares are trading lower after the company reported worse-than-expected Q2 adjusted EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:11 pm

BROS

Dutch Bros (NYSE:BROS) reported Q2 2024 adjusted EPS of $0.19, beating the $0.13 estimate by 46.15%. Sales were $324.9M, surpassing the $316.81M estimate and marking a 30.02% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:10 pm

FLNC

Fluence Energy (NASDAQ:FLNC) reported Q3 sales of $483.30 million, surpassing the analyst consensus estimate of $423.01 million by 14.25%. However, this represents a 9.89% decrease compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:10 pm

RGLD

Royal Gold (NASDAQ:RGLD) reported Q2 2024 adjusted EPS of $1.25, beating the estimate of $1.18 and showing a 42.05% increase from last year. Sales were $174.096M, surpassing the $171.370M estimate and marking a 20.86% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:10 pm

SRPT

Sarepta Therapeutics (NASDAQ:SRPT) reported Q2 2024 adjusted EPS of $0.44, significantly beating the analyst estimate of $0.01. However, the company's sales of $362.931 million missed the estimate of $391.406 million by 7.28%. Despite the miss, sales increased by 38.93% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:09 pm

HUBS

HubSpot shares are trading higher following better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:09 pm

BMBL

Bumble shares are trading lower after the company reported worse-than-expected Q2 revenue results.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:09 pm

AMPH

Amphastar Pharma (NASDAQ:AMPH) reported strong Q2 earnings, with adjusted EPS of $0.94 beating the $0.77 estimate and sales of $182.39M surpassing the $170.94M estimate. This represents significant year-over-year growth in both earnings and sales.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:09 pm

MCK

McKesson has raised its Fiscal Year 2025 Adjusted Earnings per Diluted Share guidance to a range of $31.75 to $32.55, up from the previous range of $31.25 to $32.05. This new guidance indicates a growth of 16% to 19% compared to the prior year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:09 pm